| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Top-line Data example | Phase 2b | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders | ||
Top-line Data example | Phase 2b | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders | ||
Top-line Data example | Phase 2b | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders |
Recent Updates
Recently added Catalysts
Alto Neuroscience, Inc.$27.87
+1.09 (+4.07%)
C 45Pipeline Score Fair Value Biotech · Clinical
Market Cap
744.69 M
EPS
-2.48
P/E Ratio
-
Value Trade
8.87 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
20.29 M
Operating CF
-27.09 M
Total Assets
276.26 M
Total Liabilities
32.89 M
Equity
243.37 M
D/E Ratio
12,345
-7.9 %
Week
-19.07 %
1 Month
10.06 %
3 Month
51.25 %
6 Month
-3.55 %
5 Year
-3.55 %
All Time
Cash Data
Cash Position
263.76 M
Monthly Burn
9.03 M
Runway
26.7 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
499.76 K
52 Week Range
2.15 - 28.44
% held by Insiders
9.6 %
% held by Institutions
75.13 %
Enterprise Value
504.15 M
Total Shares
35.10 M
Short %
12.25 %
Float Shares
25.27 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Alto Neuroscience, Inc.
127Total events
6Upcoming
44Tier-1 (high impact)
2023 – 2027Coverage
Upcoming catalysts 2
TBD
T2Trial Initiation
Subscribe to view catalyst details
TBD
T1Topline Readout
Subscribe to view catalyst details
Event history 2
TBD
▼Equity OfferingCorporate
Subscribe to view catalyst details
TBD
▲PublicationPramipexolePresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2024-10-31 | ALTO-100 | Phase 2b | Phase 2b | — | – | – | – |
2024-10-31 | ALTO-100 | Phase 2b | Phase 2b | — | – | – | – |
2024-10-31 | ALTO-100 | Phase 2b | Phase 2b | — | – | – | – |
Drug Pipeline Intelligence
C45
Pipeline Score $444M
Pipeline ValueFair Value
Valuation Signal5
Drugs Scored2.0x
rNPV / MCap Top 71%
Micro Cap (rank 266 of 913)
Percentile RankAlto Neuroscience, Inc. carries a moderate pipeline score (45/100), with $1.1B risk-adjusted pipeline value, led by ALTO-101 in Schizophrenia (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALTO-101 Small molecule | Schizophrenia | Phase 2 | NCT06502964 | 11% | $335M | RECRUITING | 82 | STALLED | B (60) | Mar 1, 2026 | LOW_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ALTO-207 | Major Depressive Disorder | Phase 2a | 2026-05-04 | ALTO-207 met primary and secondary endpoints demonstrating significantly greater improvements on MADRS compared to placebo. Patients randomized to receive ALTO-207 reached a mean dose of 4.1mg per day. Read More | Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting Read More | |
ALTO-207 | Major Depressive Disorder | Phase 2a | 2026-05-04 | ALTO-207 met primary and secondary endpoints demonstrating significantly greater improvements on MADRS compared to placebo. Patients randomized to receive ALTO-207 reached a mean dose of 4.1mg per day. Read More | Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting Read More | |
ALTO-207 | Major Depressive Disorder | Phase 2a | 2026-05-04 | ALTO-207 met primary and secondary endpoints demonstrating significantly greater improvements on MADRS compared to placebo. Patients randomized to receive ALTO-207 reached a mean dose of 4.1mg per day. Read More | Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ANRO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ANRO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ANRO▲ +5.9%on this news
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
Alto Neuroscience has announced the pricing of a registered direct offering of 3,776,436 shares of common stock at $26.48 per share. This offering aims to raise $100 million in gross proceeds, which will support the company's mission to develop personalized psychiatric treatments. The entire offering is being conducted by Alto Neuroscience.
Read more →ANROAlto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia
Alto Neuroscience has highlighted a publication in Nature Medicine regarding the effects of Pramipexole on anhedonia. The article suggests that the drug may have significant impacts on this condition. However, further details about the findings or implications are not provided in the text.
Read more →ANROAlto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors
Alto Neuroscience has appointed Andrew Miller, Ph.D., the founder of Karuna Therapeutics, to its Board of Directors. This strategic move is expected to enhance the company's leadership and expertise in neuroscience. Further details regarding Miller's role and contributions have not been disclosed.
Read more →ANRO▼ -7.2%on this news
Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights
Alto Neuroscience has reported its financial results for the first quarter of 2026. The report includes recent business highlights, though specific details are not provided in the article. The overall sentiment remains neutral due to the lack of substantial information regarding performance or developments.
Read more →ANROAlto Neuroscience Announces Participation in Upcoming Investor Conferences - May 11, 2026
Alto Neuroscience, a clinical-stage biopharmaceutical company, has announced its participation in upcoming investor conferences. The management team will present information on their innovative approach to neuropsychiatric disorders and their clinical-stage pipeline. Presentations will be accessible via live webcast and will include discussions on their Precision Psychiatry Platform™.
Read more →ANROAlto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting
Alto Neuroscience presented Phase 2a data for ALTO-207 targeting Major Depressive Disorder at the SOBP Annual Meeting. The presentation highlights the company's ongoing research efforts in this area. Further details on the data and its implications were not provided in the article.
Read more →ANRO▼ -6.4%on this news
Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression
Alto Neuroscience has announced the initiation of a Phase 2b trial for ALTO-207, targeting treatment-resistant depression (TRD). This trial aims to replicate positive results from the PAX-D study and is designed to address tolerability issues associated with pramipexole. Approximately 178 adults will participate, with topline data expected in late 2027.
Read more →ANROAlto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements
Alto Neuroscience announced topline data from its Phase 2 trial of ALTO-101 for cognitive impairment associated with schizophrenia. While the study did not meet primary endpoints, it showed some directional improvements in EEG measures. The company plans to focus on its lead program, ALTO-207, which is set to enter a Phase 2b trial in 2026, while exploring partnerships for ALTO-101.
Read more →ANRO▲ +9.1%on this news
Alto Neuroscience Announces $120 Million Private Placement Financing
Alto Neuroscience has announced a $120 million private placement financing to support the development of ALTO-207, a treatment for treatment resistant depression. The financing, led by Commodore Capital, will fund a planned Phase 3 clinical trial and working capital. The company anticipates initiating a Phase 2b study in early 2026 and a Phase 3 study in early 2027.
Read more →ANRO▲ +9.1%on this news
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights
Alto Neuroscience reported strong financial results for 2025, with a cash balance of $177 million. The company is advancing its pipeline, particularly ALTO-207 for treatment-resistant depression, into a pivotal Phase 2b trial. Positive validation from the PAX-D study supports their approach, although challenges remain due to adverse effects linked to pramipexole.
Read more →ANROAlto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum
Alto Neuroscience announced its participation in the Stifel 2026 Virtual CNS Forum, scheduled for March 17, 2026. The management team will engage in a virtual fireside chat, which will be accessible via a live webcast. Alto is dedicated to developing precision medicines for neuropsychiatric disorders, utilizing advanced neurobiological techniques.
Read more →ANROAlto Neuroscience Announces Participation in Upcoming Investor Conferences
Alto Neuroscience, a clinical-stage biopharmaceutical company, has announced its participation in upcoming investor conferences. The management team will present information about the company's innovative approaches to treating neuropsychiatric disorders. Alto's Precision Psychiatry Platform™ utilizes advanced techniques to identify suitable patients for its drug candidates, which target conditions like depression and schizophrenia.
Read more →ANROAlto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia
Alto Neuroscience has completed patient enrollment for its Phase 2 proof-of-concept trial of ALTO-101, aimed at treating cognitive impairment associated with schizophrenia. The study involves 83 patients across 13 sites and will assess the drug's effects on EEG measures linked to cognitive dysfunction. Topline data is expected by the end of Q1, which will inform future development decisions.
Read more →ANRO▼ -7.2%on this news
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment
Alto Neuroscience announced the publication of a review in the American Journal of Psychiatry, emphasizing neuroplasticity as a critical factor in psychiatric disorders. The review consolidates evidence linking disrupted neuroplasticity to conditions like depression and schizophrenia. It supports Alto's drug development strategy, which integrates objective biomarkers to enhance treatment efficacy.
Read more →ANROAlto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression
Alto Neuroscience has announced the issuance of a new U.S. patent for ALTO-207, a treatment for depression that combines pramipexole and ondansetron. This patent strengthens the company's intellectual property portfolio, providing protection until the mid-2040s. ALTO-207 has shown significant efficacy in clinical trials, particularly for treatment-resistant depression.
Read more →ANROAlto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology
Alto Neuroscience presented new data at the 64th annual meeting of the ACNP, focusing on their precision psychiatry platform. CEO Amit Etkin expressed excitement about the clinical milestones expected in the year ahead. The presentations included findings on EEG biomarkers related to cognitive impairment and treatment responses in various mental health conditions.
Read more →ANRO▲ +6%on this news
Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights - Successful outcome from FDA meeting on ALTO-207 in treatment-resistant depression on track to initiate Phase 2b trial in the
Alto Neuroscience reported positive third-quarter financial results for 2025, highlighting a successful FDA meeting that allows for accelerated development of ALTO-207 for treatment-resistant depression. The company has a strong cash position of $184.2 million, sufficient to support operations through 2028 and upcoming clinical trial readouts. ALTO-207 is on track for a Phase 2b trial initiation in the first half of 2026. The company also mentioned ongoing trials for ALTO-101, ALTO-300, and ALTO-100, with significant data expected in the coming year.
Read more →ANRO▲ +80.9%on this news
Alto Neuroscience Announces $50 Million Private Placement Financing - Financing led by Perceptive Advisors with participation from new and existing biotech focused investors - - Alto expects to use the proceeds of this f
Alto Neuroscience has announced a $50 million private placement financing led by Perceptive Advisors, aimed at accelerating the development of ALTO-207 for treatment resistant depression. Following a successful FDA meeting, the company intends to initiate a Phase 2b study by mid-2026, with plans for a Phase 3 study by early 2027. The investment reflects strong confidence from both new and existing institutional investors in Alto's precision psychiatry platform.
Read more →ANRO▼ -9.2%on this news
ALTO ALERT: Bragar Eagel & Squire, P.C. is Investigating Alto Neuroscience, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Alto Neuroscience on behalf of long-term stockholders after a class action complaint revealed potential breaches of fiduciary duties. The complaint alleges that the offering documents for the IPO were negligently prepared and that the efficacy of ALTO-100 for treating MDD was overstated. Following the announcement that ALTO-100 did not meet its primary endpoint in a Phase 2b trial, Alto's stock price fell nearly 70%. The law firm encourages affected investors to discuss their legal options.
Read more →ANRO▲ +7.6%on this news
Alto Neuroscience, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 19, 2025 Deadline to file Lead Plaintiff Motion.
Alto Neuroscience, Inc. investors are being advised by the Portnoy Law Firm about a class action lawsuit regarding securities purchased between February 2, 2024, and October 22, 2024. The lawsuit claims that misleading statements were made during the company's IPO about the effectiveness of its drug, ALTO-100, which failed to meet its clinical trial endpoints. Following a disappointing announcement in October 2024, the company's stock saw a significant decline, trading below its IPO price of $16.00 per share. Investors are encouraged to file a lead plaintiff motion by the September 19, 2025 deadline.
Read more →ANROALTO NEUROSCIENCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Alto Neuroscience, Inc. (ANRO) and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has announced that a class action lawsuit has been filed against Alto Neuroscience, Inc. The lawsuit is on behalf of investors who acquired securities during the specified class period between February and October 2024. Allegations include negligent preparation of IPO documents and overstated effectiveness of ALTO-100 in treating major depressive disorder (MDD), as it failed to meet primary endpoints in a recent clinical trial. Following the announcement, Alto's stock price plummeted by almost 70%.
Read more →ANROAlto Neuroscience, Inc. Class Action: The Gross Law Firm Reminds Alto Neuroscience, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 19, 2025 – ANRO
Alto Neuroscience, Inc. (NYSE: ANRO) is facing a class action lawsuit initiated by The Gross Law Firm, which seeks to represent investors who purchased shares during a specified class period. The allegations include misleading statements regarding the efficacy of the company's product, ALTO-100, in treating major depressive disorder and overstated business prospects. Shareholders are encouraged to register for participation in the lawsuit by the lead plaintiff deadline of September 19, 2025. The Gross Law Firm emphasizes its commitment to protecting investors' rights against corporate misconduct.
Read more →ANRO▲ +10.4%on this newsshared move
ALTO NEUROSCIENCE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Alto Neuroscience, Inc. (ANRO) and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Alto Neuroscience, Inc. due to allegations that the IPO offering documents were negligently prepared. The lawsuit claims that the company's drug ALTO-100 was less effective for treating major depressive disorder (MDD) than previously communicated, leading to an overestimation of its clinical and commercial prospects. Following the announcement of the drug's trial results, which did not meet its primary endpoint, Alto's stock plummeted by approximately 70%, prompting the legal action. Investors impacted during the class period from February 2, 2024, to October 22, 2024, are encouraged to consider their legal rights in this matter.
Read more →ANRO▼ -5.6%on this newsshared move
Alto Neuroscience, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before September 19, 2025 to Discuss Your Rights – ANRO
Alto Neuroscience, Inc. (NYSE: ANRO) is facing a securities lawsuit concerning alleged misleading statements made during its initial public offering in February 2024. Shareholders who purchased shares between February 2, 2024, and October 22, 2024, are encouraged to register for potential class action participation. The allegations highlight concerns regarding the effectiveness of the company’s product, ALTO-100, for treating major depressive disorder and suggest that prior statements about the company's prospects were misleading. A deadline of September 19, 2025, has been set for shareholders to register their interest in joining the lawsuit.
Read more →ANRO▲ +6%on this newsshared move
ALTO NEUROSCIENCE, INC. (NYSE: ANRO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Alto Neuroscience, Inc. Investors of Upcoming Deadline
Bernstein Liebhard LLP has issued an alert to Alto Neuroscience, Inc. investors regarding a securities fraud class action lawsuit connected to the company's February 2, 2024 IPO. The lawsuit alleges that the Company and its senior officers made misrepresentations about the clinical and commercial prospects of ALTO-100, a drug for major depressive disorder. Investors who acquired Alto securities between specified dates may want to consider their legal rights and options. A deadline for serving as lead plaintiff is set for September 19, 2025, with no fees required for representation.
Read more →ANRO▲ +6%on this newsshared move
ALTO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Alto Neuroscience, Inc. (ANRO) and Encourages Investors to Contact the Firm
A class action lawsuit has been filed against Alto Neuroscience, Inc. (ANRO) by Bragar Eagel & Squire, P.C. This legal action is on behalf of investors who acquired Alto securities between February 2, 2024, and October 22, 2024. The lawsuit claims that Alto failed to adequately disclose the ineffectiveness of ALTO-100 in treating major depressive disorder (MDD), leading to an overstated impression of the company's financial and commercial prospects. Following disappointing clinical trial results, Alto's stock experienced a significant decline.
Read more →ANROAlto Neuroscience, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 19, 2025 to Discuss Your Rights – ANRO
Alto Neuroscience, Inc. is currently involved in a class action securities lawsuit filed by Levi & Korsinsky, which seeks to recover losses for investors affected by alleged securities fraud. The complaint contends that the company made false statements regarding the effectiveness of its product pipeline, particularly ALTO-100, in treating major depressive disorder. It further claims that the clinical and commercial prospects of ALTO-100 were exaggerated, leading to materially misleading public statements about the company's financial health. Investors have until September 19, 2025, to seek appointment as lead plaintiff in the case.
Read more →ANRO▲ +5.4%on this newsshared move
ALTO NEUROSCIENCE, INC. (NYSE: ANRO) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Alto Neuroscience, Inc. Investors of Upcoming Deadline
Bernstein Liebhard LLP has issued a reminder to investors of Alto Neuroscience, Inc. regarding an upcoming deadline tied to a securities fraud class action lawsuit. The lawsuit, filed in the Northern District of California, concerns allegations of misrepresentation related to the company's drug ALTO-100, which is aimed at treating major depressive disorder. Investors who purchased shares from the company's IPO on February 2, 2024, or during a specified period, may be eligible to join the class action. A lead plaintiff must file papers by September 19, 2025, to participate actively in the litigation.
Read more →ANROAlto Neuroscience, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; September 19, 2025 Deadline to file Lead Plaintiff Motion
Alto Neuroscience, Inc. is facing a class action lawsuit initiated by investors who purchased securities during a specified class period. The lawsuit alleges that the company made misleading statements regarding the effectiveness of its drug ALTO-100 for the treatment of major depressive disorder. Following the announcement of negative trial results that failed to meet primary endpoints, the company experienced a significant decline in stock value, prompting investors to seek recovery of losses before the September 19, 2025 deadline for filing a lead plaintiff motion.
Read more →ANROAlto Neuroscience, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before September 19, 2025 to Discuss Your Rights – ANRO
A class action lawsuit has been filed against Alto Neuroscience, Inc. alleging securities fraud concerning the company's product pipeline, specifically ALTO-100. Investors who purchased shares during the initial public offering and subsequent period may be eligible to recover losses. The lawsuit claims that the company's statements about the effectiveness and commercial prospects of ALTO-100 were misleading. Affected investors have until September 19, 2025, to act.
Read more →ANROAlto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights - Acquisition of potentially best-in-class dopamine agonist combination product candidates, including ALTO-207, expands preci
Alto Neuroscience reported its financial results for Q2 2025, highlighting the acquisition of ALTO-207, a dopamine agonist combination aimed at treating treatment-resistant depression (TRD). The company plans a Phase 2b trial for ALTO-207 by mid-2026, supported by strong clinical data. Additionally, it has a solid cash reserve of about $148.1 million, expected to sustain its operations into 2028. Upcoming data readouts from related trials involving ALTO-101 and ALTO-300 are anticipated in 2025 and 2026, respectively.
Read more →ANROAlto Neuroscience, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – ANRO
Alto Neuroscience, Inc. is facing a lawsuit for securities law violations related to misleading statements made during its initial public offering. The class action involves shareholders who purchased shares between February 2, 2024, and October 22, 2024. The allegations assert that the company's product pipeline was less effective than communicated, leading to an inflation of its stock value and misrepresentation of financial prospects. The Gross Law Firm is encouraging affected investors to register for participation in the lawsuit before the deadline on September 19, 2025.
Read more →ANROALTO NEUROSCIENCE, INC. (NYSE: ANRO) INVESTOR ALERT Investors With Large Losses in Alto Neuroscience, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
Bernstein Liebhard LLP has filed a securities class action lawsuit against Alto Neuroscience, Inc. on behalf of investors who acquired shares in the company. The lawsuit alleges that the defendants made misrepresentations regarding ALTO-100, a drug for major depressive disorder. This legal action follows significant losses experienced by investors since the company's IPO on February 2, 2024. Those impacted can file to serve as lead plaintiffs, with action required by September 19, 2025.
Read more →ANRO▼ -10.5%on this news
Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203 - Demonstrated target engagement and response prediction for ALTO-203 by the
Alto Neuroscience announced positive results from its exploratory Phase 2 proof-of-concept trial of ALTO-203, a histamine H3 inverse agonist. The trial revealed significant pharmacodynamic effects, including improvements in attention and wakefulness as measured by the EEG theta beta ratio. Additionally, the study identified a robust biomarker for patient selection, enhancing the potential for targeted neuropsychiatric treatment. Although the study faced limitations such as a higher-than-expected placebo response, the results align well with prior Phase 1 findings.
Read more →ANROAlto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway - ALTO-207 (fka CTC-501) is a fixed-
Alto Neuroscience has announced the acquisition of ALTO-207, a novel dopamine agonist combination product candidate designed for treatment resistant depression. The product, previously known as CTC-501, demonstrated significant improvements in a Phase 2a trial. Alto plans to initiate a Phase 2b trial by mid-2026, expecting topline data by 2027. The acquisition aligns with the company's strategy to enhance its pipeline while maintaining a cash runway that extends into 2028.
Read more →ANRO▼ -7.2%on this news
Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights - Phase 2 proof-of-concept trials remain on track Topline data expected from ALTO-203 in MDD in the second quarter of 2025 fol
Alto Neuroscience reported its first-quarter financial results for 2025, highlighting progress in its pipeline for neuropsychiatric disorders. The company remains on track with Phase 2 proof-of-concept trials for ALTO-203 in MDD and plans for additional trials in bipolar depression and schizophrenia. Alto is well-positioned financially to support its operations and upcoming clinical milestones through 2028. Recent data enhancements support its biomarker-driven research approach, aiming to address unmet patient needs in mental health treatment.
Read more →ANROAlto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights - Favorable outcome from interim analysis of ongoing ALTO-300 Phase 2b MDD trial topline results expected in mid-2026 - - Complete
Alto Neuroscience reported its full-year 2024 financial results, highlighting key advancements in their clinical trial pipeline. Notably, interim analysis of the ALTO-300 Phase 2b trial for major depressive disorder predicts favorable outcomes to be announced in mid-2026. The company also completed enrollment in the ALTO-203 Phase 2 trial and showcased its innovative ALTO-101 for cognitive impairment in schizophrenia. With a robust cash position to support ongoing operations and clinical milestones, Alto continues to leverage its precision psychiatry approach in tackling neuropsychiatric disorders.
Read more →ANROAlto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial Interim analysis resulted in a recommendation to continue the study with a total targeted biomarker
Alto Neuroscience announced positive results from the interim analysis of its Phase 2b trial for ALTO-300, an adjunctive treatment for major depressive disorder. The analysis recommends continuing the study and expanding the biomarker population to approximately 200 patients. The company anticipates topline results in mid-2026. Alto's financial position appears solid, with an estimated $168 million cash balance expected to sustain operations until 2028.
Read more →ANRO▼ -7%on this news
Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Topline data from two MDD trials expected in the first half of 2025 Phase 2b trial of ALTO-300 as an adjunctive treatment an
Alto Neuroscience has reported its financial results for Q3 2024, revealing a robust cash position of approximately $182 million, expected to sustain operations into 2027. They anticipate topline data from two major depressive disorder (MDD) trials, ALTO-300 and ALTO-203, in the first half of 2025. Despite the ALTO-100 Phase 2b study not achieving its primary goal, notable learnings emerged from the data, particularly regarding biomarker-driven subgroups. The company continues to advance its initiatives across various neuropsychiatric indications, maintaining a focus on tailored treatment approaches.
Read more →ANROAlto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder Treatment with ALTO-100 did not demonstrate improvement in depressive symptoms compared to
Alto Neuroscience has reported disappointing topline results from a Phase 2b trial of ALTO-100 for major depressive disorder, failing to show any improvement when compared to a placebo. Despite the unfavorable trial outcomes, ALTO-100 exhibited a favorable safety and tolerability profile, consistent with previous studies. The company has a strong cash position that supports ongoing operations and future clinical milestones across their pipeline, including trials for additional candidates. The CEO expressed disappointment but emphasized the commitment to understanding the trial findings and advancing their precision medicine approach in psychiatry.
Read more →ANRO▲ +9.2%on this news
Alto Neuroscience Reports Second Quarter 2024 Financial Results and Recent Business Highlights - Completed enrollment of 301 patients in Phase 2b MDD study for ALTO-100 Investor Day focused on ALTO-100 planned for
Alto Neuroscience reported its financial results for Q2 2024, highlighting several significant advancements in its clinical programs. The company has completed enrollment in a Phase 2b study for ALTO-100 in major depressive disorder with topline data expected in October 2024. Additionally, multiple Phase 2 studies for drugs ALTO-101 and ALTO-203 have been initiated, targeting schizophrenia and major depressive disorder with anhedonia respectively. Alto's strong financial position of around $194 million will support its operations and clinical trials through at least 2027.
Read more →ANROAlto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights - Initiated Phase 2 study of ALTO-203 in patients with MDD and anhedonia-- - Reported positive Phase 1 data with transdermal f
Alto Neuroscience has reported its financial results for the first quarter of 2024, highlighting the initiation of a Phase 2 study for ALTO-203 targeting major depressive disorder (MDD) with anhedonia. The company also disclosed positive Phase 1 results for ALTO-101, a novel PDE4 inhibitor, which demonstrated better pharmacokinetic and tolerability profiles compared to oral forms. Alto's strong financial position, with cash reserves of about $206 million, is expected to sustain its operations and clinical trials through 2027. Recent developments include ongoing enrollment in several Phase 2 studies for other treatments addressing MDD and cognitive impairment.
Read more →ANROAlto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights - Reported positive results from ALTO-100 and ALTO-300 Phase 2a studies demonstrating prospective replication of response predicti
Alto Neuroscience has reported positive financial results and business highlights for the full year 2023. Key achievements include successful outcomes from Phase 2a studies for ALTO-100 and ALTO-300, along with a strong cash position following an initial public offering. The company is focused on advancing its clinical pipeline, with significant data expected in the near future from several ongoing studies. However, Alto recorded a net loss and rising expenses, which are aspects to monitor moving forward.
Read more →ANROAlto Neuroscience announced its emergence from stealth with $40 million in funding to advance the largest clinical-stage pipeline of precision psychiatry medicines. Similarly, in 2021
New York, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Precision Psychiatry Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027" - https://www.reportlinker.com/p06362627/?utm_source=GNW The global precisio
Read more →ANROAlto Neuroscience Emerges with Largest Clinical-Stage Precision Psychiatry Pipeline and $40 Million in Financing
--Advancing 11 clinical-stage assets across psychiatric conditions with Phase 2 data readouts in MDD and PTSD for each of its three lead candidates expected by mid-2023-- --Over $40 million in capital raised, including a $32 million Series A investment led by Apeiron Investment
Read more →Competitive Position
How ANRO ranks across every disease it competes inCompetitive Position is a premium feature
See how ANRO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial